165 related articles for article (PubMed ID: 30710219)
1. Effect of sofosbuvir and daclatasvir on lipid profile, glycemic control and quality of life index in chronic hepatitis C, genotype 3 patients.
Jain A; Kalra BS; Srivastava S; Chawla S
Indian J Gastroenterol; 2019 Feb; 38(1):39-43. PubMed ID: 30710219
[TBL] [Abstract][Full Text] [Related]
2. Sofosbuvir-based therapies in genotype 2 hepatitis C virus cirrhosis: A real-life experience with focus on ribavirin dose.
Smirne C; D'Avolio A; Bellan M; Gualerzi A; Crobu MG; Pirisi M
Pharmacol Res Perspect; 2021 Aug; 9(4):e00811. PubMed ID: 34152088
[TBL] [Abstract][Full Text] [Related]
3. Sofosbuvir-Daclatasvir is suboptimal in patients with genotype 2 chronic hepatitis C infection: real-life experience from the HEPATHER ANRS CO22 cohort.
de Lédinghen V; Lusivika-Nzinga C; Bronowicki JP; Zoulim F; Larrey D; Metivier S; Tran A; Marcellin P; Samuel D; Chazouillères O; Chevaliez S; Dorival C; Fontaine H; Pawlotsky JM; Carrat F; Pol S;
J Viral Hepat; 2020 Oct; 27(10):964-973. PubMed ID: 32436335
[TBL] [Abstract][Full Text] [Related]
4. Association between interleukin 28B polymorphism and sustained virological response to sofosbuvir plus daclatasvir in chronic hepatitis C genotype 4 Egyptian patients.
Hassanien KS; El-Sayed EM; Ismail RS; Zakarya ZM; Helal GK
J Clin Pharm Ther; 2021 Aug; 46(4):942-949. PubMed ID: 33768560
[TBL] [Abstract][Full Text] [Related]
5. Cure or curd: Modification of lipid profiles and cardio-cerebrovascular events after hepatitis C virus eradication.
Huang CF; Dai CY; Yeh ML; Huang CI; Lee HC; Lai WT; Liang PC; Lin YH; Hsieh MY; Hou NJ; Lin ZY; Chen SC; Huang JF; Chuang WL; Yu ML
Kaohsiung J Med Sci; 2020 Nov; 36(11):920-928. PubMed ID: 32643842
[TBL] [Abstract][Full Text] [Related]
6. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection.
Sulkowski MS; Gardiner DF; Rodriguez-Torres M; Reddy KR; Hassanein T; Jacobson I; Lawitz E; Lok AS; Hinestrosa F; Thuluvath PJ; Schwartz H; Nelson DR; Everson GT; Eley T; Wind-Rotolo M; Huang SP; Gao M; Hernandez D; McPhee F; Sherman D; Hindes R; Symonds W; Pasquinelli C; Grasela DM;
N Engl J Med; 2014 Jan; 370(3):211-21. PubMed ID: 24428467
[TBL] [Abstract][Full Text] [Related]
7. Impact of sustained virological response on metabolic disorders in diabetic chronic hepatitis C virus patients after treatment with generic sofosbuvir and daclatasvir.
Abdo M; Rabiee A; Abdellatif Z; Abdel Alem S; Moustafa A
Eur J Gastroenterol Hepatol; 2021 Dec; 33(12):1588-1594. PubMed ID: 32804853
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of Glycated Haemoglobin (HbA1c) Level in Type 2 Diabetic Chronic HCV Non-cirrhotic Treatment-Naïve Egyptian Patients Eradicated with Sofosbuvir Plus Daclatasvir.
Hussein HA; Allam AS; Moaty ASA
Curr Diabetes Rev; 2020; 16(2):165-170. PubMed ID: 31146663
[TBL] [Abstract][Full Text] [Related]
9. Sofosbuvir with NS5A inhibitors in hepatitis C virus infection with severe renal insufficiency.
Singh A; Kumari S; Kumar P; De A; Singh V
J Viral Hepat; 2018 Dec; 25(12):1501-1506. PubMed ID: 30113115
[TBL] [Abstract][Full Text] [Related]
10. Daclatasvir: A NS5A Replication Complex Inhibitor for Hepatitis C Infection.
Smith MA; Regal RE; Mohammad RA
Ann Pharmacother; 2016 Jan; 50(1):39-46. PubMed ID: 26486762
[TBL] [Abstract][Full Text] [Related]
11. Retreatment with sofosbuvir, ledipasvir, and add-on ribavirin for patients who failed daclatasvir and asunaprevir combination therapy.
Suda G; Ogawa K; Yamamoto Y; Katagiri M; Furuya K; Kumagai K; Konno J; Kimura M; Kawagishi N; Ohara M; Umemura M; Ito J; Izumi T; Nakai M; Sho T; Natsuizaka M; Morikawa K; Tsubota A; Shimada N; Iio E; Tanaka Y; Sakamoto N;
J Gastroenterol; 2017 Oct; 52(10):1122-1129. PubMed ID: 28315983
[TBL] [Abstract][Full Text] [Related]
12. Daclatasvir vs telaprevir plus peginterferon alfa/ribavirin for hepatitis C virus genotype 1.
Jacobson I; Zeuzem S; Flisiak R; Knysz B; Lueth S; Zarebska-Michaluk D; Janczewska E; Ferenci P; Diago M; Zignego AL; Safadi R; Baruch Y; Abdurakhmanov D; Shafran S; Thabut D; Bruck R; Gadano A; Thompson AJ; Kopit J; McPhee F; Michener T; Hughes EA; Yin PD; Noviello S
World J Gastroenterol; 2016 Mar; 22(12):3418-31. PubMed ID: 27022224
[TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of dual therapy with daclatasvir and asunaprevir for older patients with chronic hepatitis C.
Morio R; Imamura M; Kawakami Y; Morio K; Kobayashi T; Yokoyama S; Kimura Y; Nagaoki Y; Kawaoka T; Tsuge M; Hiramatsu A; Nelson Hayes C; Aikata H; Takahashi S; Miki D; Ochi H; Mori N; Takaki S; Tsuji K; Chayama K
J Gastroenterol; 2017 Apr; 52(4):504-511. PubMed ID: 27631593
[TBL] [Abstract][Full Text] [Related]
14. SD1000: High Sustained Viral Response Rate in 1361 Patients With Hepatitis C Genotypes 1, 2, 3, and 4 Using a Low-cost, Fixed-dose Combination Tablet of Generic Sofosbuvir and Daclatasvir: A Multicenter, Phase III Clinical Trial.
Merat S;
Clin Infect Dis; 2020 May; 70(10):2206-2212. PubMed ID: 31504303
[TBL] [Abstract][Full Text] [Related]
15. Real-world effectiveness and safety of sofosbuvir plus daclatasvir with or without ribavirin for genotype 2 chronic hepatitis C in Taiwan.
Cheng PN; Chiu YC; Chien SC; Chiu HC
J Formos Med Assoc; 2019 May; 118(5):907-913. PubMed ID: 30316677
[TBL] [Abstract][Full Text] [Related]
16. Diagnostic approach to elucidate the efficacy and side effects of direct-acting antivirals in HCV infected patients.
Younas S; Mukhtar H; Gohar UF; Alsrhani A; Alzahrani B; Junaid K; Qamar MU; Ejaz H
J Infect Dev Ctries; 2021 Oct; 15(10):1489-1496. PubMed ID: 34780372
[TBL] [Abstract][Full Text] [Related]
17. Treatment of chronic genotype-3 hepatitis C virus infection using direct-acting antiviral agents: An Indian experience.
Goel A; Bhargava R; Rai P; Aggarwal R
Indian J Gastroenterol; 2017 May; 36(3):227-234. PubMed ID: 28656492
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and tolerability of sofosbuvir and daclatasvir for treatment of hepatitis C genotype 1 & 3 in patients undergoing hemodialysis- a prospective interventional clinical trial.
Cheema SUR; Rehman MS; Hussain G; Cheema SS; Gilani N
BMC Nephrol; 2019 Nov; 20(1):438. PubMed ID: 31779583
[TBL] [Abstract][Full Text] [Related]
19. All-oral daclatasvir plus asunaprevir for chronic hepatitis C virus (HCV) genotype 1b infection: a sub-analysis in Asian patients from the HALLMARK DUAL study.
Kao JH; Lee YJ; Heo J; Ahn SH; Lim YS; Peng CY; Chang TT; Torbeyns A; Hughes E; Bhore R; Noviello S
Liver Int; 2016 Oct; 36(10):1433-41. PubMed ID: 27009831
[TBL] [Abstract][Full Text] [Related]
20. Viral kinetics analysis and virological characterization of treatment failures in patients with chronic hepatitis C treated with sofosbuvir and an NS5A inhibitor.
Fourati S; Guedj J; Chevaliez S; Nguyen THT; Roudot-Thoraval F; Ruiz I; Soulier A; Scoazec G; Varaut A; Poiteau L; Francois M; Mallat A; Hézode C; Pawlotsky JM
Aliment Pharmacol Ther; 2018 Mar; 47(5):665-673. PubMed ID: 29271114
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
